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ABSTRACT
Anxiety and mood disorders have become very significant affections in the last decades. According to WHO at least one mental 
disease occurred per year in 27% of EU inhabitants (more than 82 mil. people). It is estimated that by 2020, depression will be the main 
cause of morbidity in the developed countries. These circumstances call for research for new prospective drugs with anxiolytic and 
antidepressive properties exhibiting no toxicity and withdrawal effect and possessing beneficial properties, like antioxidant and/or 
neuroprotective effects. The aim of this study was to obtain information about psychopharmacological properties of pyridoindole 
derivatives SMe1EC2 and SMe1M2, using non-invasive behavioral methods in rats.
The battery of ethological tests (open field, elevated plus-maze, light/dark box exploration, forced swim test) was used to obtain 
information about anxiolytic and antidepressant activity of the pyridoindole derivatives. The substances were administered intraperi-
toneally 30 minutes before the tests at doses of 1, 10 and 25 mg/kg. 
In the behavioral tests, SMe1EC2 was found to exert anxiolytic activity in elevated plus maze with no affection of locomotor activity. 
The highest dose of SMe1M2 increased the time spent in the lit part of the Light/Dark box, however this result was influenced by 
inhibition of motor activity of the rats. Similar findings were observed also in elevated plus-maze, although these results were not 
statistically significant. 
In conclusion, from the results of our study it is evident that both pyridoindoles acted on the CNS. In the highest dose, SMe1M2 was 
found to possess rather sedative than anxiolytic or antidepressant activity.
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resulting in somatic manifestations of anxiety, including 
shortness of breath, sweating, nausea, rapid heartbeat, 
and elevated blood pressure (Sandford et al., 2000).
Generalized anxiety disorder (GAD) is the most com-
mon of the anxiety disorders, with a lifetime prevalence 
of approximately 5% (Wittchen & Hoyer, 2001). More 
than 27% of adult Europeans are estimated to experience 
at least one form of mental ill health during any one year 
(Wittchen & Jacobi, 2005). The most common forms 
of mental ill health in the EU are anxiety disorders and 
depression. By the year 2020, depression is expected to 
be the highest ranking cause of disease in the developed 
world (WHO, 2001). Currently, in the EU, some 58,000 
citizens die by suicide every year, more than the annual 
deaths from road traffic accidents, homicide, or HIV/
AIDS (European Commission, 2005). 
Introduced over 40 years ago, benzodiazepines (BZs) 
quickly became the most widely used psychotropic 
drugs. However in recent years, attitudes toward these 
Introduction
Psychiatric disorders have accompanied mankind from 
the beginning of its existence. Compared to the pass, the 
current hectic lifestyle is far more complicated, affect-
ing the social environment. Fast, unpredicted changes 
cause increased pressure, requiring repeated adjustment. 
Sometimes these adaptations trigger a cascade of unpre-
dicted events, which may lead to self-destructive behavior 
or even suicide. 
Anxiety is defined as a state of unwarranted or inap-
propriate worry, often accompanied by restlessness, 
tension, distraction, irritability, and sleep disturbances, 
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compounds have greatly changed, and growing awareness 
and concern about dependence liability, withdrawal phe-
nomena, and short- and long-term side effects have made 
the long-term use of these compounds into question able 
(Basile et al., 2004). The search has begun for compounds 
chemically unrelated to BZs with more specific therapeu-
tic actions and without concomitant unwanted effects. 
Pyridoindol compounds such as [6-Fluoro-9-methyl-2-
phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1H-
pyridol[3,4-b]indol-1-one] have proved to be full agonists 
(in electrophysiological assays) at GABAA2 receptors, and 
may have the clinical potential as anxiolytics and muscle 
relaxants (Licata et al., 2005).
Both pyridoindoles SMe1EC2 and SMe1M2 were 
derived from the pyridoindol stobadine (STO) [(–)-cis-
2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]
indole] is derived from the gamma-carboline antide-
pressant and neuroleptic drug Carbidine® as its active 
(–)-enantiomer. Preclinical safety evaluation of STO was 
performed in rats (Gajdošíkova et al., 1995), beagle dogs 
(Majerčík et al., 1984) and in vitro in human fibroblastoid 
cells (Chalupa et al., 1993) and no adverse effects were 
detected. It crosses readily the blood brain barrier and 
has cardioprotective, neuroprotective and antihypoxic 
properties (Horákova and Štolc, 1998). Moreover, long-
term administration of STO resulted in increased levels 
of dopamine and serotonin (Dubovický et al., 1997). Based 
on STO, new pyridoindole derivatives with improved 
pharmacodynamic and toxicity profiles have been 
developed on applying molecular design, synthesis and 
adequate tests. A total of >70 derivatives have so far been 
prepared. These derivatives have low toxicity (LD50 after 
p.o. administration > 2000 mg/kg – Štolc et al., 2008). 
This study was the first experiment with the pyri-
doindole SMe1M2, yet for SMe1EC2, better knowledge 
on toxicity, antioxidant properties and neuroprotection 
is available. Ujházy et al. (2008; 2011) did not find any 
maternal, embryofetal neurobehavioral toxicity in their 
safety studies. A positive neuroprotective effect was also 
observed in 2-month-old male rats by improved recovery 
of neuronal function after transient hypoxia/hypoglyce-
mia in reoxygenation, as well as by morphological changes 
manifested as reduced edema extent in the treated hippo-
campus under ischemia in vitro (Gáspárová et al., 2009). 
The aim of this study was to assess psychophar-
macological properties of the pyridoindole derivatives 
SMe1EC2 and SMe1M2, using non-invasive behavioral 
methods in rats.
Material and methods
Animals
Eighty 3–4 months-old adult male Wistar rats 
(Department of Toxicology and Breeding Station at 
Dobrá Voda; Slovakia) weighing approximately 250±50 g 
were used for the study. The rats were acclimatized to the 
animal housing facility for 10 days prior to experimental 
procedures. The animals were housed in polypropylene 
cages measuring 35  ×  55  ×  20  cm, covered by a stainless 
steel netted lid, placed in groups of 4. The bedding mate-
rial consisted of wood chips. The animals had free access 
to standard pelleted diet (KKZ rat/mouse, registration 
number SK 100089) and water. Ambient temperature 
and relative humidity were maintained at approximately 
22±2 °C and 55 ± 10%, respectively. The animal room was 
illuminated by artificial light from fluorescent tubes on a 
12-h light/dark cycle, lit during the day from 7 a.m. 
All procedures were performed in compliance with the 
Principles of Laboratory Animal Care issued by the Ethical 
Committee of the Institute of Experimental Pharmacology 
and Toxicology, Slovak Academy of Sciences and by the 
State Veterinary and Food Administration of the Slovak 
Republic. 
Drugs
Pyridoindol derivatives (code names SMe1EC2 and 
SMe1M2) were prepared at the Institute of Experimental 
Pharmacology and Toxicology, Slovak Academy of 
Sciences. The substances tested were dissolved in saline at 
a constant dosage volume 0.1 ml/100 g body weight. Each 
rat was treated intraperitoneally at a single dose of 1, 10 or 
25 mg/kg 30 minutes before the behavioral test. Controls 
received vehicle.
Experimental procedures
The animals were assigned to groups according to their 
basal motor activity measured using an open field (base 
42 × 42 cm, height 40 cm) equipped with Actitrack (Panlab, 
S. L., Spain). The apparatus software recorded locomotor 
activity of the animal by registering the beam interrup-
tions caused by movements of the body. All behavioral 
experiments were performed 30 min after i.p. injection 
of the drugs.
Open field test
The standard open field test is commonly used to assess 
locomotor, exploratory and anxiety-like behavior in labo-
ratory animals (rats/mice). This test is particularly useful 
for evaluation of the anxiolytic and anxiogenic effects of 
drugs, locomotor responses to drugs as well as behavioral 
responses to novelty.
The open field used in this experiment consisted of 
a 60  ×  40  cm plastic apparatus, closed with 25  cm-high 
walls. The apparatus was kept in a room under dim light 
and the tests were undertaken during the light-on phases 
of the cycle, between 9 a.m. and 1 p.m. In order to elimi-
nate any olfactory cues, the apparatus was cleaned with 
mild detergent after each individual test. Each session was 
started by placing the rat in the central area and lasted 
5 min. Two animals were tested simultaneously and the 
rats´ movements were tracked with two digital cameras 
and the movies were analyzed by computer software 
ANY-Maze (Stoelting Europe, Ireland).
Elevated plus maze
The standard elevated plus maze test is commonly used to 
assess anxiety-like behavior in laboratory animals (rats/213
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mice). The maze is a cross-shaped elevated maze, with 
two open arms and two closed arms. The elevated plus 
maze task approaches the conflict between the innate 
fear that rodents have in open areas versus their desire 
to explore new environment. Security is provided by the 
closed arms whereas the open arms offer exploratory 
value. When anxious, the natural tendency of rodents is to 
prefer enclosed dark spaces to opened brightly lit spaces. 
In this context, anxiety-related behavior is measured by 
the degree to which the rodent avoids the unenclosed 
arms of the maze.
All parts of the apparatus were made of dark polyvi-
nyl plastic. The arms of the maze were 50 cm above the 
floor, 50 cm long and 10 cm wide. Two animals were 
tested simultaneously. The rats’ movements were tracked 
with two digital cameras and the movies were analyzed 
by computer software ANY-Maze (Stoelting Europe, 
Ireland). Lighting was provided by a string of rope lights 
attached to the underside of the open arms of the maze. 
Each session was started by placing the rat in the central 
area facing the open arms of the maze and lasted 5 min. 
Between trials, the maze was wiped with a mild detergent.
Light/Dark Test 
The test apparatus consisted of white plastic arena 
(60 × 40 cm) with black plastic box (40 × 20 × 40 cm, open-
ing 10 × 8 cm) inserted in the arena. An incandescent light 
bulb fixed 1 m above the arena provided the illumination 
so that the light intensity in the center of the illuminated 
box was 200 lux. At the beginning of the experiment, a 
rat was placed in the illuminated box, facing the opening. 
The apparatus was equipped with digital camera and the 
movies were analyzed by computer software ANY-Maze 
(Stoelting Europe, Ireland). The following parameters 
were recorded during a 5-min period: (a) time spent by 
rats in the lit box; (b) time spent by rats in the dark box; 
(c) attempt at entry into the lit box followed by avoidance 
responses. 
Statistical analysis
The data were analyzed by means of one-way ANOVA 
followed by LSD post hoc test. The data are expressed 
as mean ± S.E.M. The significance limit of p<0.05 was 
considered statistically significant.
Results
SMe1EC2 anxiolytic properties 
Fisher LSD post-hoc analysis revealed that only the highest 
dose increased the activity of rats in the open arms of the 
elevated plus maze (p<0.05) (Figure 1). We also noticed an 
increasing trend of time spent in the open arms depend-
ing on the dose administered. 
We discovered that animals tended to be less anxious 
also in the light/dark test only after treatment with highest 
dose. However, this result was not statistically significant 
(Figure 2). No differences were seen in locomotor activity 
tested in open field. 
SMe1M2 anxiolytic properties 
Administration of SMe1M2 increased the immobility in 
the open field (p=0.05; Figure 3). Similarly were influenced 
also the following parameters tested. Animals receiving 
the highest dose of SMe1M2 spent significantly more 
time in the lit part of the light/dark box (p<0.05; Figure 4) 
and the activity in the open arms was also influenced in a 
dose-dependent manner (Figure 5).
Discussion
Problems of mental health are still tabooed. Cancer 
research is predominant and well supported while mental-
health research is focused mainly on neurodegenerative 
diseases such as Alzheimer’s, rather than on earlier-onset 
conditions that can undermine peoples’ entire lives, such 
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Figure 1. Anti-anxiety behavior manifested in rats treated with 
highest dose of SMe1EC2. DZP – diazepam 2.5 mg/kg; *p<0.05 – 
signifi  cantly diff  erent compared to controls (ANOVA).
Figure 2. Time spent in the lit part of the Light/Dark Box . 
DZP – diazepam (positive control).214
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as depressive disorders. It is startling that approximately 
one mental disease has found to occurr per year in 27% 
of EU inhabitants, representing more than 82 million 
people. WHO (2001) estimated that by 2020 depression 
would be the main cause of morbidity in the developed 
countries.
The aim of this study was to assess psychopharma-
cological properties of two pyridoindole derivatives 
SMe1EC2 and SMe1M2 synthesized at the Institute of 
Experimental Pharmacology and Toxicology. We used a 
non-invasive ethological approach of behavioral analysis. 
Both derivatives originate from stobadine (STO), whose 
molecule was studied in detail and no adverse effects were 
observed (Gajdošíková et al., 1995; Balonová et al., 1991; 
Dubovický et al., 1999). STO is an optic stereoisomer 
of the neuroleptic drug γ-carboline Carbidine® (Barkov, 
1973). Our results showed possible anxiolytic proper-
ties of SMe1EC2. The substance did not influence the 
motor activity at the doses tested and the elevated plus 
maze test revealed dose-dependent decrease of anxiety 
behavior after treatment with SMe1EC2. The highest 
dose increased the activity of rats in the open arms. The 
activity of rats treated with the dose of 1 mg/kg was com-
parable to that of control rats, however the time spent in 
the intersection was increased, indicating an anti-anxiety 
type of behavior. Similar results were seen in the light/
dark box. 
The second derivative, SMe1M2, caused a dose-
dependent decrease in motor activity seen in open field 
as well as elevated plus maze. The effect of the highest 
dose (25 mg/kg) was statistically significant. We did not 
observe anti-anxiety behavior similar to that of SMe1EC2. 
Increased immobility could be responsible for false posi-
tive results in the light/dark box test. Animals receiving 
the highest dose spent significantly more time in the lit 
part of the box compared to controls. 
Even though benzodiazepines are relatively safe drugs 
and are widely used in the treatment of anxiety, they may 
produce untoward side effects such as sedation, memory 
impairment, tolerance, and physical dependence (Griebel 
et al., 2001).
Pharmacological effects of benzodiazepines are pro-
duced through positive allosteric modulation of the action 
o f  G A B A  a t  i o n o t r o p i c  G A B A A receptors (Braestrup 
& Squires, 1977; Mohler & Okada, 1977; Barnard et al., 
1998). The classical benzodiazepines interact indiscrimi-
nately with heterogenous GABAA receptor subtypes, 
and possess numerous useful and also unwanted phar-
macological actions. Researchers therefore search for 
compounds chemically unrelated to the benzodiazepines, 
with eliminated unwanted side effects and more specific 
therapeutic actions. 
The clinically used benzodiazepines are full agonists. 
Attempts have been made to develop compounds which 
are anxioselective in that they retain the anxiolytic 
properties of the full agonist, but have reduced sedation 
and dependence (withdrawal) liabilities. Such com-
pounds may interact with all four (i.e. α1-, α2-, α3- and 
α5-containing) GABAA receptor subtypes and have 
partial rather than full agonist efficacies. Examples of 
nonselective partial agonists include bretazenil, imidaz-
enil, FG 8205, abecarnil, NS 2710, pagoclone, RWJ-51204 
and (S)-desmethylzopiclone (Atack, 2003). Recently there 
has been more evidence pointing toward pyridoindole 
derivatives as possible replacement of benzodiazepines 
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Figure 3. Sedative behavior manifested in rats treated with 
SMe1M2. DZP – diazepam 2.5 mg/kg; *p<0.05 – signifi  cantly 
diff  erent compared to controls (ANOVA).
Figure 4. Anti-anxiety behavior manifested in rats treated with 
highest dose of SMe1EC2. DZP – diazepam 5 mg/kg; *p<0.05 – 
signifi  cantly diff  erent compared to controls (ANOVA).
Figure 5. Dose-dependent inhibition of locomotor activity after 
treatment with SMe1M2. DZP – diazepam 2.5 mg/kg; *p<0.05 – 
signifi  cantly diff  erent compared to controls (ANOVA).215
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in treatment of anxiety disorders. Behavioral studies 
in r oden ts sh o w ed tha t S L65 1 498 ( [ 6- Fl u o r o- 9- metyl -
2-fenyl-4-(pyrolidin-1-yl-karbonyl)-2,9-dihydro-1H-
pyridol[3,4-b]indol-1-one]) had anxiolytic-like activity 
similar to that of diazepam (Griebel et al. 2001, 2003). 
The SL651498 induced muscle weakness, ataxia, or seda-
tion occurred at doses much higher than those producing 
anxiolytic-like activity (Griebel et al., 2001). 
Similar to the findings of Griebel et al. (2001), we 
observed anxiolytic properties of our pyridoindole 
derivative SMe1EC2. Moreover, our chosen dose range 
did not induce motor activity depression and immobility. 
SMe1M2 produced a greater inhibitory effect on overall 
motor activity with significant increase in immobility. 
Several authors reported that compared to benzodiaz-
epines non-selective partial agonists of GABAA receptors 
e.g. bretazenil, imedazenil and Y-23684, possessed better 
anxiolytic properties and did not induce such prominent 
inhibition of motor activity. It is estimated that the 
sedative and anxiolytic action of GABAA receptors are 
mediated via α1 and α2 GABAA receptors (Crestani et 
al., 2000; Löw et al., 2000; Rudolph et al., 1999). These 
autors have suggested that the α1-subunit is responsible 
for sedative effects and the α2-subunit for their anxiolytic 
properties. 
Our results showed that the pyridoindoles SMe1EC2 
and SMe1M2 synthesized at the Institute of Experimental 
Pharmacology and Toxicology influenced the subtle func-
tion of the CNS controlling anxiety and/or alertness of 
animals. It is evident that SMe1M2 affected locomotor 
activity and the doses used induced sedative-like behav-
ior. This study was the first experiment with SMe1M2 and 
the doses were chosen according to a previous study of 
pyridoindole derivatives. With optimalization of the dose 
it is still to be elucidated if this pyridoindole possesses 
similar anxiolytic properties as SMe1EC2. Taking into 
account that these derivatives have excellent antioxidant 
and neuroprotective properties and exhibit low toxicity, 
they might represent new directions in the treatment of 
anxiety disorders.
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